Critical Path opportunities list
This article was originally published in The Gray Sheet
Executive Summary
FDA unveiled its 76-item opportunities list March 16, identifying biomarker development and clinical trial design as areas of focus for the Critical Path initiative. Device-related projects include developing surrogate outcomes for drug-eluting stent trials, establishing objective measures of the effectiveness of intraocular lenses, and creating computer models to predict effects of implanted devices prior to human testing. The list also includes nine priorities for "advancing the use of new imaging techniques" such as FDG-positron emission tomography, intravascular ultrasound and high-resolution chest computed tomography. The list has been in development since FDA announced its Critical Path initiative in March 2004 with the intent to streamline the regulatory pathway for new biomedical discoveries (1"The Gray Sheet" Jan. 9, 2006, p. 4)...
You may also be interested in...
Imaging Is Key To Product Development In Critical Path Opportunities List
Imaging techniques hold "vast potential" to help speed the development of new medical products, FDA says in the latest report on its Critical Path initiative
Critical Path Will Lead To Device Research Opportunities In ’06 – Woodcock
A formal Critical Path priority list to be released in the coming year will include device-focused initiatives, assured FDA Deputy Commissioner for Operations Janet Woodcock
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.